To investigate the accumulative effect of FoxC2 and E-cadherin expression on the prognosis of NSCLC, patients were classified into 4 groups: Group 1, low FoxC2 and preserved E-cadherin (n = 69); Group 2, low FoxC2 and impaired E-cadherin (n = 158); Group 3, high Foxc2 and preserved E-Cadherin (n = 47); and Group 4, high Foxc2 and impaired E-cadherin (n = 35). This evidence concerns the gene FOXC2 and non-small cell lung carcinoma.